(NP (NP Transient/JJ pseudohypoaldosteronism/NN) (PP in/IN (NP obstructive/JJ renal/JJ disease/NN)) (PP with/IN (NP (NP transient/JJ reduction/NN) (PP of/IN (NP lymphocytic/JJ aldosterone/NN receptors/NNS)))) ./.)
(NP (NP Results/NNS) (PP in/IN (NP two/CD affected/JJ infants/NNS)) ./.)
(S (NP-SBJ We/PRP) (VP report/VBP (NP (NP two/CD patients/NNS) (PP with/IN (NP (NP transient/JJ pseudohypoaldosteronism/NN) (PP due/JJ to/TO (NP obstructive/JJ renal/JJ disease/NN)))))) ./.)
(S (NP-SBJ Both/DT patients/NNS) (VP presented/VBD (PP with/IN (NP a/DT salt-losing/JJ episode/NN simulating/VBG adrenal/JJ insufficiency/NN))) ./.)
(S (PP In/IN (NP one/CD patient/NN)) ,/, (NP-SBJ-90 (NP transient/JJ reduction/NN) (PP of/IN (NP aldosterone/NN receptors/NNS))) (VP could/MD (VP be/VB (VP documented/VBN (NP *-90/-NONE-) ,/, (SBAR while/IN (S (PP in/IN (NP the/DT second/JJ patient/NN)) (NP-SBJ the/DT (ADJP-COOD (ADJP clinical/JJ) and/CC (ADJP biochemical/JJ)) parameters/NNS) (VP were/VBD (ADJP-PRD consistent/JJ (PP with/IN (NP transient/JJ pseudohypoaldosteronism/NN))))))))) ./.)
(S (NP-SBJ-91 Aldosterone/NN receptors/NNS) (VP were/VBD (ADJP-PRD normal/JJ) (PP in/IN (NP both/DT patients/NNS)) (SBAR-TMP (WHADVP-92 when/IN) (S (NP-SBJ-93 *-91/-NONE-) (VP studied/VBN (NP *-93/-NONE-) (PP-TMP after/IN (NP (NP the/DT surgical/JJ correctionNN) (PP of/IN (NP the/DT obstruction/NN)))) (ADVP *T*-92/-NONE-))))) ./.)
